Efficacy of Crushed Delayed-Release Posaconazole Tablets in Rhino-Orbito-Cerebral Mucormycosis

Resource type
Journal Article
Authors/contributors
Title
Efficacy of Crushed Delayed-Release Posaconazole Tablets in Rhino-Orbito-Cerebral Mucormycosis
Abstract
A significant proportion of patients with Rhino-orbito-cerebral mucormycosis (ROCM) develop oroantral fistulas. Due to the unclear efficacy of crushed delayed-release posaconazole tablets (DRPT) via nasogastric tube in this group of patients, clinicians often use inferior alternatives like posaconazole suspension. In this prospective study, we report good plasma concentrations (median, 2,639 ng/mL; interquartile range [IQR], 1,690 to 3,575 ng/mL; and range, 1,004 to 4,835ng/mL) and complete cure and survival at 3 and 6 months in 19 such patients.
Publication
Antimicrobial Agents and Chemotherapy
Date
2022-12-20
Volume
66
Issue
12
Pages
e01085-22
Journal Abbr
Antimicrob Agents Chemother
Accessed
1/28/23, 8:23 AM
ISSN
0066-4804, 1098-6596
Language
en
Library Catalog
DOI.org (Crossref)
Citation
Manesh, A., Devasagayam, E., Bhanuprasad, K., Mathew, S. K., Karthik, R., Mathew, B. S., & Varghese, G. M. (2022). Efficacy of Crushed Delayed-Release Posaconazole Tablets in Rhino-Orbito-Cerebral Mucormycosis. Antimicrobial Agents and Chemotherapy, 66(12), e01085-22. https://doi.org/10.1128/aac.01085-22
DRUGS AND THERAPIES
Link to this record